EQ earnings analysis
What we found in EQ's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Equillium’s Q2 2026 results showed improved operating efficiency, with diluted EPS improving to $(0.04) from $(0.16) year over year, R&D expense declining by $1.334 million, and six-month operating cash burn improving to $8.408 million. Cash increased to $57.164 million after $35.388 million of financing inflows, and management believes the balance funds operations into 2029. However, the company has no product revenue, reported a $226.2 million accumulated deficit, expects continued losses and additional funding needs, and faces heightened clinical, dilution, supply-chain and potential cryptocurrency-strategy risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Loss Narrowed Year Over Year
- Diluted EPS was $(0.04) in Q2 2026 versus $(0.16) in Q2 2025, an improvement of $0.12 per share year over year. Six-month diluted EPS was $(0.10) versus $(0.40).
- R&D Spending Fell 33%
- Research and development expense declined to $2.749 million from $4.083 million in Q2 2025, a $1.334 million decrease, primarily reflecting the wind-down of the EQUATOR study and lower headcount.
- Year-to-Date Loss Improved
- Six-month net loss declined to $10.004 million from $14.393 million in the prior-year period, an improvement of $4.389 million.
- Cash Balance More Than Doubled
- Cash and cash equivalents increased to $57.164 million at June 30, 2026 from $30.277 million at December 31, 2025, primarily supported by $35.388 million of financing cash inflows.
- Operating Cash Burn Declined
- Operating cash burn improved to $8.408 million in the first six months of 2026 from $11.182 million in the prior-year period. Capital expenditures were only $74,000, versus $4,000 in the prior-year period.
- EQ504 Development Remains on Track
- Management plans to initiate the EQ504 Phase 1 proof-of-mechanism study in Q4 2026, with data expected approximately six months later, while stating that existing cash should fund operations into 2029.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Additional Funding Remains Necessary
- The company states it will require substantial additional funding to complete development and commercialization. The March 2026 financing generated approximately $35.0 million gross proceeds, but the company still had an accumulated deficit of $226.2 million and expects continued operating losses.
- Uninitiated Crypto Strategy Adds Risk
- The filing newly highlights a potential cryptocurrency treasury reserve strategy, although the company has not initiated it. The company states it may use proceeds from future offerings to purchase cryptocurrencies, which could expose capital to substantial volatility and liquidity risk.
- Tariff and BIOSECURE Supply Risk
- The filing adds specific exposure to international trade restrictions, including potential tariffs on pharmaceutical products and ingredients and restrictions under the BIOSECURE Act. Management states tariffs could increase R&D expenses and disrupt supply, while principal suppliers of critical materials are located in the U.S., Europe and China.
- Clinical and Revenue Execution Risk
- Development remains concentrated in pre-commercial assets: the company has not generated product sales and expects product revenue is unlikely within the next 12 months, if ever. EQ504 Phase 1 initiation is planned for Q4 2026, but management provides no assurance that the study will begin on time or produce favorable data.
- Significant Future Dilution
- Potential dilution is substantial: 48,515,298 pre-funded warrant shares were reserved as of June 30, 2026, and up to 35,087,717 additional shares or pre-funded warrants may be issued upon achievement of milestones under the August 2025 financing.
- Persistent Operating Losses
- The company continues to report negative cash generation and losses, including $8.408 million of operating cash used in the first six months of 2026 and a $226.2 million accumulated deficit at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
- Segment
- Single operating and reportable segment; no product sales have been generated. Q2 2026 R&D expense was $2.749 million and G&A expense was $2.406 million.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects to initiate an EQ504 Phase 1 proof-of-mechanism study in Q4 2026, with data expected approximately six months thereafter, and expects cash and cash equivalents as of June 30, 2026 to fund operations into 2029.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Equillium reported disappointing financial results for the first quarter of 2026, with revenues of $0.2 million, coming in slightly above estimates, while the EPS of -$0.04 exceeded expectations of -$0.07. Despite a…
- 10-K · March 25, 2026
- Equillium is a preclinical-stage biopharma focused on two lead programs: EQ504 (AhR modulator) and EQ302 (oral IL-15/IL-21 inhibitor). The company plans to initiate a Phase 1 proof‑of‑mechanism study for EQ504 in…
- 10-Q · November 13, 2025
- Equillium reported $0 revenue for the three months ended September 30, 2025 (vs $12,161 in Q3 2024) while cutting R&D spend sharply to $1,301 for the quarter (from $9,562). The company completed an equity financing…
- 10-Q · August 14, 2025
- Equillium reported Q2 2025 revenue of $0 and a net loss of $5.739 million (diluted EPS -$0.16), versus revenue of $13.853 million and net income of $0.468 million in Q2 2024. Management paused R&D during Q2 pending…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EQ makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever